Symjepi, the prefilled epinephrine syringe that’s not quite an auto-injector but is intended for similar use during anaphylactic episodes, gained FDA approval during June of last year.
Hailed as an inexpensive alternative to traditional auto-injectors, its introduction was supposed to usher in a new era of competition in the epinephrine market. That introduction was delayed while Adamis played catch-up in an effort to find a partner to commercialize the device and bring it to market.
Yesterday, the company announced they had finally inked a deal with the Sandoz division of Novartis to commercialize Symjepi for the US market.
Said Dr Dennis J Carlo, President and CEO of Adamis:
We are very excited about our collaboration with Sandoz. They are among the top pharmaceutical companies in the world and we believe they have the commercial presence and proven track record to maximize the value of Symjepi. We believe the financial terms of this agreement have the potential to bring meaningful recurring revenue to Adamis and we look forward to growing, and possibly expanding, this partnership with Sandoz based on the future success of Symjepi in the market.
We at SnackSafely.com hope this collaboration enables both partners to quickly introduce Symjepi to a market starved for competition.
While perhaps not an ideal solution for many families, Symjepi does provide an option for circumstances where a trained individual is available to administer the device, such as by parent, school nurse, emergency responder, et al.
We anticipate the price of the device will be significantly lower than traditional auto-injectors due to the simplicity of the design, and that this in turn will put downward pressure on pricing for the entire market.
Our fingers are crossed.
